Clinical Trial

A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder

Name: A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder — clinical trial record (NCT07177677)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASD

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This clinical trial aims to evaluate the safety and preliminary efficacy of intravenous administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs) in patients with autism spectrum disorder (ASD).

Trial Details

NCT Number	NCT07177677
Lead Sponsor	Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. Collaborators: Capital Medical University
Conditions	Autism Spectrum Disorder
Enrollment	42 participants
Start Date	2025-09-30
Primary Completion	2026-12-30 (estimated)
Study Completion	2028-08-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-17